NCT04895735 2026-02-02
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT04209660 2025-10-07
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03087019 2022-10-14
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed